Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

20022,026 citationsJournal Articlebronze Open Access

Authors

Hagop Kantarjian · The University of Texas MD Anderson Cancer Center

Charles L. Sawyers

Andreas Hochhaus · Heidelberg University

François Guilhot · Centre Hospitalier Universitaire de Poitiers

Charles A. Schiffer

Carlo Gambacorti‐Passerini · Azienda Ospedaliera San Gerardo

Dietger Niederwieser · Leipzig University

Debra Resta

Abstract

Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.

Topics & Keywords

Chronic Myeloid Leukemia Treatments Chronic Lymphocytic Leukemia Research Eosinophilic Disorders and Syndromes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 346, Issue 9, pp. 645-652

DOI: 10.1056/nejmoa011573

Field-Weighted Citation Impact: 79.63